NEPTUNE WELLNESS SOLUTIONS INC. Spending and interest coverage
- R&D / revenue · 12 months: Value 0.21%; Formula and calculation Research and development expense / revenue. Period ending 2023-12-31..
- Stock-based compensation / revenue · 12 months: Value 5.61%; Formula and calculation Share-based compensation / revenue. Period ending 2023-12-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2023-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 0.21% | Research and development expense / revenue. Period ending 2023-12-31. $80.37K ÷ $38.99M × 100 ≈ 0.21% |
| Stock-based compensation / revenue · 12 months | 5.61% | Share-based compensation / revenue. Period ending 2023-12-31. $2.19M ÷ $38.99M × 100 ≈ 5.61% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 80.37K USD | Research and Development Expense |
| Revenue | 38.99M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 2.19M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -74.55M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $80.37K | $38.99M | $2.19M | $-74.55M | (m) | 0.21% | 5.61% | (m) | (m) |
| 2023-09-30 | $108.48K | $43.32M | $2.76M | $-63.91M | (m) | 0.25% | 6.37% | (m) | (m) |
| 2023-06-30 | $291.40K | $46.36M | $1.41M | $-99.11M | $2.71M | 0.63% | 3.05% | -36.63× | Reported |
| 2023-03-31 | $484.22K | $51.74M | $3.50M | $-102.85M | $2.00M | 0.94% | 6.77% | -51.43× | Reported |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $835.17K | $53.84M | $7.44M | $-83.80M | $997.22K | 1.55% | 13.82% | -84.03× | Reported |
| 2022-03-31 | $880.15K | $47.70M | $7.82M | $-88.53M | $1.00M | 1.85% | 16.39% | -88.53× | Reported |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $1.92M | $34.26M | $9.89M | $-130.87M | $293.25K | 5.61% | 28.85% | -446.29× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.